uniQure N.V.
QURE
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.03B
Close$
$-8.56
119.6% downside
Current Fair Value
119.6% downsideOvervalued by 119.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.03 Billion |
|---|---|
| Enterprise Value | $2.68 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.46 |
| Beta | 0.9 |
| Outstanding Shares | 66,243,879 |
Return
| Return on Equity | -77.83% |
|---|---|
| Return on Assets | -25.60% |
| Return on Invested Capital | -29.63% |
Valuation & Multiples
| P/E Ratio | -10.8 |
|---|---|
| PEG | -9.4 |
| Price to Sales | - |
| Price to Book Ratio | 10.92 |
| Enterprise Value to Revenue | 143.33 |
| Enterprise Value to EBIT | -10.02 |
| Enterprise Value to Net Income | -11 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.19 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 4, 2026
EPS Estimate
$-0.82
Average shareholder expectationRevenue Estimate
$5.45 M
Average shareholder expectationNext Earnings Call
Expected Date
November 9, 2026
EPS Estimate
$-0.90
Average shareholder expectationRevenue Estimate
$6.21 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 14.82% |
|---|---|
| Total Calls | 2,735▼ 99.98% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 6.51%▼ 97.26% |
|---|---|
| Total Invested | $188.04M▼ 80.63% |
| Investors Holding | 42▼ 216.00% |
ESG Score
No data
About uniQure N.V.
uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to tr...